Kornimate/medical-research-clean huggingface dataset:
evaluation of efficacy of combination of pregabalin and antioxidant in reducing pain in chronic pancreatitis: a randomized control trial

Conditions: Chronic Pancreatitis

Summary: study hypothesis: combination of antioxidants and pregabalin results in better pain relief than placebo in patients with chronic pancreatitis. chronic pancreatitis (cp) is a clinical enigma, with pain being the most distressing symptom that brings the patient to clinical attention. pain in chronic pancreatitis is multifactorial, and may be related to pancreatic ductal hypertension, tissue hypertension, inflammatory cytokines, oxidative stress and neuropathic mechanisms like mechanical allodynia, inflammatory hyperalgesia and temporal summation. the mainstay of treatment for pain in cp due to pancreatic ductal stone is endotherapy (eswl and ercp). recent randomized controlled trials have shown that antioxidant cocktail and pregabalin (a presynaptic voltage gated calcium channel blocking agent) can result in significant reduction of pain in cp. in this study, the investigators will study the efficacy of the combination of antioxidants and pregabalin in reducing pain and compare that with placebo. the investigators will randomize patients with documented chronic pancreatitis with recurrent/persistent pain after undergoing endotherapy and ductal clearance into three groups: group a- antioxidants + pregabalin; group b- placebo. the primary outcome will be change in pain score and the secondary outcomes will be change in the number of painful days, analgesic requirements, quality of life and depression scale. pain score will be quantified by the izbicki pain score and visual analog scale; while quality of life and depression will be measured by the eortc qlq-c30/pan26 and beck depression inventory respectively. comparison between group a vs b will be made by the chi square test/fischer exact and the student's 't' tests respectively and analysis will be done on a intention to treat and per protocol basis. with an expected improvement of pain by 40% (at 80% power and alpha of 0.05) and adjusting for a presumed 10% drop out rate, the required sample size in each group will be at least 40.


Eligibility criteria:
inclusion criteria: 1. epigastric pain +/- radiation at least thrice in one month over the past three month. 2. endotherapy/surgery and ducal clearance exclusion criteria: 1. age \ 65yrs 2. mpd and biliary obstruction 3. pancreatic neoplastic lesions 4. acute flare 5. pancreatic pseudocysts 6. pregnancy 7. cardiac and renal diseases 8. use of other anti epileptics 9. hypersensitivity to gabapentin/pregabalin

Keywords: chronic pancreatitis pregabalin antioxidant
characterization of the metabolic fate of an oral arginine form

Conditions: Overweight; Hypertriglyceridemic Waist

Summary: the purpose of this study is to compare the metabolic fate of two oral forms of l-arginine in healthy subjects featuring metabolic syndrome related risk factors

the study is a randomized crossover study including 16 healthy subjects with risk factors for metabolic syndrome and 16 healthy control subjects. according a double crossover design, each subject received two oral forms of l-arginine (a and b) in random order, and participated in a exploration day on the first day of arginine administration and after one week of supplementation with this arginine form. the two weeks of arginine supplementation were separated by a washout period of 2 weeks at least. each exploration extended over 24 hours after administration of the first arginine dose. blood tests were performed at 0, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 h after administration of the first dose. during explorations after the supplementation period, we also collected urine (0, 2, 4, 8, 12, 24 h after the first dose).

Eligibility criteria:
healthy subjects with 'hypertriglyceridemic waist' : inclusion criteria: * age between 18 to 60 years old * overweight (bmi between 25 and 30 kg/m²) * 'hypertriglyceridemic waist' (waist circumference \> 94cm for men or \> 88cm for women and fasting triglyceride levels \> 150 mg/dl) exclusion criteria: * obesity (bmi\> 30 kg / m²) * cardiac or vascular diseases * diabetes * thyroid disease * systolic blood pressure \> 150 mmhg or diastolic blood pressure \> 90 mmhg * tobacco consumption \> 6 cigarettes per week * alcohol consumption\> 3 drinks per day * any medication (except contraceptive treatment) or dietary supplement intake that could not be arrested more than a week before the first visit for the duration of the study. * persons under guardianship * pregnancy (positive beta-hcg blood test) * positive serology hbsag achbc, hcv and hiv * hemoglobin \< 14 g/dl (for men) or \<12 g / dl (for women) * participation in a clinical trial within 6 months preceding the study healthy control subjects : inclusion criteria: * age between 18 to 60 years old * normal weight (bmi between 18.5 and 25 kg/m²) * waist circumference \< 94cm for men or \< 88cm for women and fasting triglyceride levels \< 150 mg/dl exclusion criteria : * cardiac or vascular diseases * diabetes * thyroid disease * systolic blood pressure \> 150 mmhg or diastolic blood pressure \> 90 mmhg * tobacco consumption \> 6 cigarettes per week * alcohol consumption\> 3 drinks per day * any medication (except contraceptive treatment) or dietary supplement intake that could not be arrested more than a week before the first visit for the duration of the study. * persons under guardianship * pregnancy (positive beta-hcg blood test) * positive serology hbsag achbc, hcv and hiv * hemoglobin \< 14 g/dl (for men) or \<12 g / dl (for women) * participation in a clinical trial within 6 months preceding the study

Keywords: arginine supplementation metabolic syndrome nitric oxide
epidemiology of h. pylori transmission

Conditions: Communicable Diseases

Summary: this observational epidemiologic study with nested cross-sectional and longitudinal aims will evaluate host immune response to mixed chronic infections (helicobacter pylori, latent tuberculosis, intestinal helminthiasis) in recent us immigrants.

1750 clinically-well, adult (age 18-55 years), recent immigrants (\<2 years u.s. residence), referred through cooperating public health clinics in the santa clara valley area, ca will be screened for h. pylori, helminth, and latent tuberculosis infections \["screening" population\]. of these 1750, 426 will be selected for more intensive study (cohort population), 105 of whom will receive baseline endoscopy. of those selected for the cohort, 300 are expected to complete a 9-month follow-up assessment, 75 of whom are expected to undergo a second follow-up endoscopy.

Eligibility criteria:
inclusion criteria: * between 18-55 years of age * either sex * if female not pregnant or breastfeeding * lived in the united states less than 2 years * healthy * scheduled for tuberculosis skin test (tst) exclusion criteria: * under 18 and older than 55 years of age, * pregnant or breastfeeding * have lived in unites states more that 2 years * chronic illness * not planning to get a tst

Keywords: chronic coinfection
physical work capacity after traumatic brain injury

Conditions: Traumatic Brain Injury

Summary: the purpose of this study is to determine whether body weight supported treadmill training is more effective than traditional physical therapy at restoring gait in persons recovering from traumatic brain injury.


Eligibility criteria:
inclusion criteria: * traumatic brain injury * follow two step commands * between 18 and 60 years old * between 3 and 36 months post injury exclusion criteria: * known cardiovascular disease * uncooperative, behavioral challenges

Keywords: rehabilitation head injury 3 months post injury require manual assistance or walking aids to walk very slow walking speed able to follow two step commands
efficacy of covid-19 vaccination in patientstreated with anti-cd20 for follicular lymphoma or mantle cell lymphoma

Conditions: Follicular Lymphoma; Mantle Cell Lymphoma

Summary: the anti-cd20 monoclonal antibodies, rituximab (r) and obinutuzumab (g), are used as standard maintenance therapy every 2 months for 2 to 3 years in patients with follicular lymphoma (fl) or mantle cell lymphoma (mcl). this treatment is associated with profound and prolonged b lymphopenia, hypogammaglobulinemia and increased infections. severe forms of covid-19 on rituximab with prolonged carriage of the virus have been reported due to significant impairment of humoral immunity in this context of maintenance therapy. therefore, during the covid-19 epidemic, clinicians are faced with the question of whether to discontinue maintenance therapy or continue treatment. however, the half-life of rituximab is 29 days and lymphopenia continues for up to 9-12 months after stopping injections. therefore, it is not clear that discontinuation of maintenance therapy will alter the risk of severe sars-cov-2. however, post-vaccination immunization against sars-cov-2 by an mrna vaccine is not known in this context of prolonged treatment with rituximab or obinutuzumab. it is however well established that post-vaccination responses against diphtheria, tetanus, pneumococcus, hbv, or influenza in particular are altered after anti-cd20 antibodies. if the humoral response is crucial in the post-vaccination response, it is also suggested that the preservation of innate immunity and the cd8 response, unaltered by anti-cd20, could also play an important role in the post-vaccination response and virus clearance. the aim of our study is to evaluate the humoral and post-vaccination t-cell response based on serological data and t-cell production of interferon gamma in response to sars-cov-2 specific antigens (elispot interferon gamma) in this group of patients treated for lymphoma with a long-term anti-cd20 antibody.


Eligibility criteria:
inclusion criteria: * age superior to 18 years old * patient undergoing maintenance treatment for mantle cell lymphoma or follicular lymphoma treated with rituximab or obinutuzumab in complete remission or stable disease between injection #1 and injection #13 or 19 (end of second year or third year) * inform consent signed exclusion criteria: * documented history of sars-cov-2 infection less than 3 months old * progressive lymphoma * contraindication sars-cov-2 vaccination (allergy) * refusal of sars-cov-2 vaccination * patient who has been off rituximab or obinutuzumab therapy for more than 6 months * patient not covered by health system * pregnant or nursing woman

Keywords: sars-cov-2 immunization vaccination rituximab obinutuzumab maintenance
evaluating the efficacy of artesunate in adults with mild symptoms of covid-19

Conditions: Covid 19 Positive; Corona Virus Infection

Summary: coronavirus disease (covid-19) is an infectious disease caused by a newly discovered coronavirus. at this time, there are no specific vaccines or treatments for covid-19. however, there are many ongoing clinical trials evaluating potential treatments drugs used to treat malaria infection has shown to be beneficial for many other diseases, including viral infections. in this clinical trial, investigators will evaluate the effect of artemisinin / artesunate on morbidity of covid-19 patients in decreasing the course of the disease and viral load in symptomatic stable positive swab covid-19 patients. investigators are hypothesizing that due to the antiviral properties of this drug it will help as a treatment for the covid -19 patients. in improving their condition and clearing the virus load,

in this clinical trial, investigators will evaluate the effect of artemisinin / artesunate on morbidity of covid-19 patients in decreasing the course of the disease and viral load in symptomatic stable positive swab covid-19 patients. investigators are hypothesizing that due to the antiviral properties of this drug it will help as a treatment for the covid -19 patients. in improving their condition and clearing the virus load, investigators are testing two groups the one that will take the drug and then compare them to a placebo group that will not take any drug for the treatment in a blinded fashion made by randomization done by our pharmacy team so investigators eliminate risk of bias. our expectation is to find a total reduction of the hospital stay to 7 days instead of 14 days currently indicating the effectiveness of the medication in eradicating the virus.

Eligibility criteria:
inclusion criteria: * adult patient age more than 18 and less than 60 years * symptomatic , positive swab covid-19 patients * patients who have mild to moderate symptoms * patients who have no risk factors like * patients who is not on other medications rather those on supportive care exclusion criteria: * · patients who have sever disease- shortness of breath, sick patients or admitted in icu * patients who are receiving ventilation supports * high risk group like :- age more than 60 years, chronic heart diseases, chronic lungs diseases, diabetes, immunocompromised diseases or on immune suppression medications or pregnant women * patients who are on other medications which used as treatment for covid 19

Keywords: artemisinin artesunate
using cardiopulmonary exercise test as an incentive to outpatient cardiac rehabilitation for acute coronary syndrome survivors.

Conditions: Acute Coronary Syndrome

Summary: exercise-based cardiac rehabilitation is a class i recommendation for acute coronary syndrome (acs) patients. however, participate rate of outpatient rehabilitation is quite low and remains a global issue. the study is to propose a strategy in order to encourage post-acs patients to participate in the outpatient cardiac rehabilitation.

background: exercise-based cardiac rehabilitation is a class i recommendation for acute coronary syndrome (acs) patients. however, participate rate of outpatient rehabilitation is quite low and remains a global issue. the study is to propose a strategy in order to encourage post-acs patients to participate in the outpatient cardiac rehabilitation. hypothesis: cardiopulmonary exercise test (cpet) incentives acs survivors to participate in outpatient cardiac rehabilitation. objectives: 200 acs survivors who are eligible for cardiac rehabilitation will be allocated randomly into control and experimental groups. method: before discharge, both control and experimental groups will be informed of the importance of cardiac rehabilitation and invited to participate the outpatient rehabilitation. the experimental group will also be told that an important examination, i.e. the cpet, will be performed in order to evaluate their heart function at the outpatient department (opd). primary outcome: the presence of acs survivors at the opd of rehabilitation in order to receive the rehabilitation/cpet. secondary outcomes: the adherence to cardiac rehabilitation, defined as completing a full course of cardiac rehabilitation (6 sessions) or home-based exercise. factors that might influence the presence of acs survivors at opd of rehabilitation will also be recorded and analyzed, including: * patient characteristics: age, sex, body mass index (bmi), cardiovascular disease (cvd) risk factors * electrocardiography (ecg): st elevation myocardial infarction (stemi) or non st elevation myocardial infarction (nstemi) * lab data: peak troponin level. * days of hospitalization. statistics: t-test, anova

Eligibility criteria:
inclusion criteria: * acute coronary patients exclusion criteria: * acute illness that stayed in hospital for more than 2 weeks. * patients who received surgical intervention * severe complications (ex. respiratory failure, stroke, acute renal failure) * contraindications of cardiopulmonary exercise testing * patients who cannot perform the cardiopulmonary exercise testing

Keywords: cardiac rehabilitation cardiopulmonary exercise testing
prevention of imminent paralysis following spinal cord trauma or ischemia by minocycline: a multi-center study in israel with idf primary care involvement

Conditions: Spinal Tumors, Trauma Patients, Minocycline.

Summary: spinal cord trauma and the consequent paraplegia are possibly among the most devastating injuries in soldiers and during spine surgery, and are significant in the medical, social and financial aspects. limited mobility, the need for assistance in all human activities, shame, and many medical complications related directly to the neural deficits make paraplegia an important target for prevention. our study will evaluate the efficacy of minocycline in two different groups: 1. minimizing the neurological damage among trauma patients. 2. preventing neurological damage through operation in spinal tumors patients. 2.objectives the primary objectives of the trial are to determine: 1. efficacy of administrating minocycline in minimizing the neurological damage among acute spinal cord injury patients and spinal cord tumors (primary and metastases) patients? 2. efficacy of administrating minocycline at changing the natural history and rehabilitation of spinal cord trauma patients. 3. safety of applying minocycline in spinal cord injuries patients and spinal cord tumors?


Eligibility criteria:
inclusion criteria: trauma patients with incomplete spinal cord syndromes related to fractures, dislocations, blunt trauma (central cord syndrome). 1. inclusion criteria: 2. patients with incomplete spinal cord syndromes related to fractures, dislocations, blunt trauma (central cord syndrome). 3. ages: 18 to 65 4. males - including those involved in active military duty. 5. females - of child-bearing potential who have a negative pregnancy test (hcg urine) within 72 hours of informed consent. pregnant women will be excluded from the study. exclusion criteria: 1. complete cord transection, severe head injury, coma, or other disease of the cns, and spinal injury diagnosed later than 24 hours. 2. pregnant women (minocycline can cause fetal harm) and children. 3. lower extremity fractures, mildly reduced consciousness and frail cognitive status will not be considered for exclusion. 4. patients who will not be enrolled will be listed and reason for non inclusion will be recorded. spinal tumors: inclusion criteria: 1. intrathecal extramedullary tumors, vertebral metastases or primary vertebral tumors causing cord compression with or without incomplete cord syndrome. exclusion criteria: 1.intramedullary tumors or tumors causing complete cord syndrome -
impact of glasses for vision problems on cognitive function in rural older adults

Conditions: Cognition Disorders

Summary: the aim of this project is to explore whether vision correction can effectively slow cognitive decline in older adults. the primary question it seeks to answer is: can providing free near and/or distance vision correction glasses to older adults with refractive errors or uncorrected vision, who have normal baseline cognition and hearing, reduce the rate of cognitive decline over 36 months in a cost-effective manner? researchers will compare the rate of cognitive decline over 36 months between older adults who receive refractive correction and those who do not.


Eligibility criteria:
inclusion criteria: * older adults who meet all of the following criteria will be eligible to participate in this study: * age ≥ 65 years; * reside in the sample county and plan to remain there throughout the study; * normal baseline cognitive function or mild cognitive impairment (hmse score \> 18); * presence of uncorrected or inadequately corrected refractive error (i.e., distant vision \< 6/18 or near vision \< n6); * able to accept random assignment and interventions, and willing to adhere to the study protocol; * voluntarily sign an informed consent form to participate in the entire study process. exclusion criteria: * age under 65 years; * hmse cognitive function score ≤ 18; * non-refractive visual decline (e.g., cataracts, glaucoma, or other severe ocular diseases); * severe mobility impairment requiring long-term bed rest or wheelchair use; * severe systemic diseases, including heart and liver failure, end-stage renal disease, malignancies, major neurological diseases, mental disorders, and/or other conditions that affect life expectancy or interfere with cognitive testing; * self-reported hearing impairment, unable to pass the whisper test; * use of hearing aids; * severe aging or end-of-life status.
prospective memory in parkinson's disease

Conditions: Memory; Prospective Memory; Parkinson's Disease

Summary: the investigators tested whether prospective memory is impaired in individuals with parkinson's disease compared to controls using reliable and validated experimental measures. also, the investigators assessed the impact of parkinson's medication on prospective memory performance in pd to better estimate prospective memory function in pd patients' everyday (chronically treated) life.


Eligibility criteria:
inclusion criteria: * pd group: * clinically definite pd * 40-70 years old * hoehn and yahr stage i,ii,iii * currently treated with levodopa/carbidopa * control group: * 40-70 years old * spouses of pd group preferred exclusion criteria: * pd group and control group: * significant neurological problems * significant current psychiatric diagnoses * mini mental status exam score \< 24 (mmse) * any significant abnormality on brain imaging * mptp exposure * control participants met the same exclusion criteria described above as well as a biological family history of pd

Keywords: prospective memory performance prospective memory outcome parkinson's disease
ropivacaine use in femoral nerve block; what is the minimal effective analgesic concentration (meac 90)

Conditions: Postoperative Pain

Summary: the aim of this study is to determine the minimal effective ropivacaine concentration required to provide adequate analgesic femoral nerve block in 90% of patients (meac90)

* before induction of ga, all patients will receive sciatic, obturator, lateral femoral cutaneous and femoral nerve blocks. * the femoral nerve block will be performed using 15ml of ropivacaine which concentration relied on the response of the previous patient. * based on biased-coin design up-down sequential method: when a patient has a negative response, the next patient will receive a concentration 0.01% w/v higher. however if he has a positive response, the next patient will be randomized to receive either the same ropivacaine concentration or a concentration 0.01% w/v less. * patients with pain free recovery will be considered to have positive response. * patients' responses will be analyzed to calculate the meac90

Eligibility criteria:
inclusion criteria: * patients, who are scheduled for knee ligament reconstruction exclusion criteria: * \<18 y, * asa physical class greater \>iii * bmi \>40 has any contraindication for medications or techniques used in the study